The use of injections to treat structural muscle injuries is controversially discussed. In our controlled in vitro study, we investigated the biological impact of Actovegin and Traumeel alone and in combination on primary human skeletal muscle cells. Cells were characterized by immunofluorescence staining for myogenic factor 5 (Myf5) and MyoD, and cultured with or without Actovegin and / or Traumeel. The effects of these agents were assayed by cell viability and gene expression of the specific markers MyoD, Myf5, neural adhesion molecule (NCAM), and CD31. Myotube formation was determined by myosin staining. Neither Actovegin nor Traumeel showed toxic effects or influenced cell viability significantly. High volumes of Actovegin down-regulated gene expression of NCAM after 3 days but had no effect on MyoD, Myf5, and CD31 gene expression. High volumes of Traumeel inhibited MyoD gene expression after 3 days, whereas after 7 days MyoD expression was significantly up-regulated. The combination of both agents did not significantly influence cell viability or gene expression. This is the first study demonstrating that Actovegin and Traumeel potentially modulate human skeletal muscle cells. The relevance of these in vitro findings has to be highlighted in further in vivo studies.
2
Orchard JW,
Best TM,
Mueller-Wohlfahrt HW,
Hunter G,
Hamilton BH,
Webborn N,
Jaques R,
Kenneally D,
Budgett R,
Phillips N,
Becker C,
Glasgow P.
The early management of muscle strains in the elite athlete: Best practice in a world with a limited evidence basis. Br J Sports Med 2008; 42: 158-159
3
Wright-Carpenter T,
Klein P,
Schaferhoff P,
Appell HJ,
Mir LM,
Wehling P.
Treatment of muscle injuries by local administration of autologous conditioned serum: A pilot study on sportsmen with muscle strains. Int J Sports Med 2004; 25: 588-593
5 MS AH Mohamed Ali MR Yusof A George J Lee LP Platelet-rich plasma injections for the treatment of hamstring injuries: A randomized controlled trial. Am J Sports Med 2014; 42: 2410-2418
6
Reurink G,
Goudswaard GJ,
Moen MH,
Weir A,
Verhaar JA,
Tol JL.
Myotoxicity of injections for acute muscle injuries: A systematic review. Sports Med 2014; 44: 943-956
9
Ueblacker P,
English B,
Mueller-Wohlfahrt HW.
Nonoperative treatment and return to play after complete proximal adductor avulsion in high-performance athletes. Knee Surg Sports Traumatol Arthrosc 2016; 24: 3927-3933
12
Wright-Carpenter T,
Opolon P,
Appell HJ,
Meijer H,
Wehling P,
Mir LM.
Treatment of muscle injuries by local administration of autologous conditioned serum: Animal experiments using a muscle contusion model. Int J Sports Med 2004; 25: 582-587
15
Reichl FX,
Holdt LM,
Teupser D,
Schutze G,
Metcalfe AJ,
Hickel R,
Hogg C,
Bloch W.
Comprehensive analytics of Actovegin(R) and its effect on muscle cells. Int J Sports Med 2017; 38: 809-818
16
Buchmayer F,
Pleiner J,
Elmlinger MW,
Lauer G,
Nell G,
Sitte HH.
Actovegin(R): A biological drug for more than 5 decades. Wien Med Wochenschr 2011; 161: 80-88
17
Vanden Bossche L,
Vanderstraeten G.
A multi-center, double-blind, randomized, placebo-controlled trial protocol to assess Traumeel injection vs. dexamethasone injection in rotator cuff syndrome: The TRAumeel in ROtator cuff syndrome (TRARO) study protocol. BMC Musculoskelet Disord 2015; 16: 8
18
Porozov S,
Cahalon L,
Weiser M,
Branski D,
Lider O,
Oberbaum M.
Inhibition of IL-1beta and TNF-alpha secretion from resting and activated human immunocytes by the homeopathic medication Traumeel S. Clin Dev Immunol 2004; 11: 143-149
20
Livak KJ,
Schmittgen TD.
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001; 25: 402-408
23
Astashkin EI,
Glezer MG,
Vinokurov MG,
Egorova ND,
Orekhova NS,
Novikova AN,
Grachev SV,
Yurinskaya MM,
Sobolev KE.
Actovegin reduces the ROS level in blood samples of heart failure patients and diminishes necrosis of SK-N-SH human neuroblastoma cells. Dokl Biol Sci 2013; 448: 57-60
25
Miltenburger HG,
Baschong W,
Horner V,
Marx G.
Cooperative effects in vitro on fibroblast and keratinocyte functions related to wound healing by transforming growth factor-beta and a low molecular weight fraction from hemolyzed blood. Arzneimittelforschung 1994; 44: 872-876
26
Brock J,
Golding D,
Smith PM,
Nokes L,
Kwan A,
Lee PYF.
Update on the role of Actovegin in musculoskeletal medicine: A review of the past 10 years. Clin J Sport Med 2018;
29
Schneider C.
Traumeel – an emerging option to nonsteroidal anti-inflammatory drugs in the management of acute musculoskeletal injuries. Int J Gen Med 2011; 4: 225-234
